文献速递心力衰竭与心肌病

2021年心血管医学年度回顾:心力衰竭与心肌病

The year in cardiovascular medicine 2021: heart failure and cardiomyopathies.
PubMed 文献 · Eur Heart J · 2022-01-01

2021年发布了心力衰竭的通用定义与分类,将心衰定义为由心脏异常引起并伴有钠尿肽升高或心源性淤血客观证据的临床综合征,并分为射程降低、轻度降低和保留射血分数三类。2021年ESC指南对射血分数降低心衰患者使用达格列净和恩格列净给予I类推荐;EMPEROR-Preserved试验中恩格列净减少了心血管死亡与心衰住院的复合终点,成为射血分数保留心衰的首个循证治疗。

要点

  • 心衰通用定义强调症状/体征、心脏异常及钠尿肽或淤血证据。
  • 2021 ESC指南对HFrEF患者使用达格列净或恩格列净给予I类推荐。
  • 恩格列净减少HFpEF患者心血管死亡与心衰住院复合终点。

核心结论

  • 2021年心衰领域确立了通用定义与分类,并更新了HFrEF和HFpEF的治疗证据。

研究设计与样本

  • 本文为2021年心血管医学年度回顾,总结心衰与心肌病领域的关键文献与指南。

主要发现

  • EMPEROR-Preserved试验中恩格列净减少了HFpEF患者心血管死亡与心衰住院的复合终点。
  • 2021年多项报告对沙库巴曲缬沙坦、SGLT2抑制剂、盐皮质激素受体拮抗剂、羧基麦芽糖铁、可溶性鸟苷酸环化酶激动剂和心肌肌球蛋白激活剂等治疗进行了分析。
  • 在COVID-19住院患者中,急性心衰和心肌损伤较常见,而心肌炎和心脏长期损伤不常见。

关键数值与推荐

  • 心衰通用定义:由心脏异常引起并伴有钠尿肽升高或心源性淤血客观证据的临床综合征。
  • 心衰分类包括HFrEF、射血分数轻度降低和HFpEF,与2021 ESC指南一致。
  • 2021 ESC指南对HFrEF患者使用达格列净和恩格列净给予I类推荐。

临床怎么用

  • 按通用定义和分类评估心衰患者,并依据2021 ESC指南对HFrEF患者应用SGLT2抑制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the year 2021, the universal definition and classification of heart failure (HF) was published that defines HF as a clinical syndrome with symptoms and/or signs caused by a cardiac abnormality and corroborated by elevated natriuretic peptide levels or objective evidence of cardiogenic congestion. This definition and the classification of HF with reduced ejection fraction (HFrEF), mildly reduced, and HF with preserved ejection fraction (HFpEF) is consistent with the 2021 ESC Guidelines on HF. Among several other new recommendations, these guidelines give a Class I indication for the use of the sodium-glucose co-transporter 2 (SGLT2) inhibitors dapagliflozin and empagliflozin in HFrEF patients. As the first evidence-based treatment for HFpEF, in the EMPEROR-Preserved trial, empagliflozin reduced the composite endpoint of cardiovascular death and HF hospitalizations. Several reports in 2021 have provided novel and detailed analyses of device and medical therapy in HF, especially regarding sacubitril/valsartan, SGLT2 inhibitors, mineralocorticoid receptor antagonists, ferric carboxymaltose, soluble guanylate cyclase activators, and cardiac myosin activators. In patients hospitalized with COVID-19, acute HF and myocardial injury is quite frequent, whereas myocarditis and long-term damage to the heart are rather uncommon.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Bauersachs, de Boer, Lindenfeld, et al. The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. Eur Heart J. 2022. PMID: 34974611. doi:10.1093/eurheartj/ehab887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。